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Abstract  
Introduction: Coronavirus Disease (COVID‐19) has become the most important global health issue, and chest 
computed tomography (CT) scan can help determine the severity of the infection. 
Objectives: This study aimed to provide an emergency scoring tool for predicting 30-day adverse outcomes 
in non-critical new-onset COVID-19 patients.   
Methods: This derivation study was conducted on new-onset COVID-19 patients presenting to the emergency 
department of an urban teaching hospital in Tehran, Iran, between 20 February and 20 March 2020. The total 
lobe severity score (TSS), age, history of comorbidities, and 30-day adverse outcomes (death, ICU admission 
or intubation) were taken into account to produce three prediction models.  
Results: Overall, 137 patients were included in the study. Their mean age was 59.9±16.8 years and 62% were 
male. The ground glass nodule, patch B/punctate ground-glass opacity, fibrous stripes, and air bronchogram 
sign with perihilar distribution, bilateral and ≥ 2 affected lobes were the most common findings. The mean TSS 
(model 1) was significantly higher in patients with an adverse outcome (9.4±3.2) compared to the discharged 
patients (7.2±3.3) (p<0.001, AUC: 0.703, sensitivity: 64.4% and specificity: 74.1%). The optimal cut-off point 
of model 2 (TSS and age) had the following parameters: AUC: 0.721, sensitivity: 71.2% and specificity: 67.2%. 
The optimal cut-off point of model 3 (TSS, age, comorbidities) had: AUC: 0.755, sensitivity: 79.7% and 
specificity: 65.5%. The discrimination achieved with model 3 based on Bonferroni’s test was significantly 
better than that achieved with TSS (p<0.001).  
Conclusion: TSS combined with age and history of at least one comorbidity had a better predictive value for 
adverse outcomes with a cut-off point above 8. 
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INTRODUCTION
COVID‐19 is a highly contagious disease that is 
spreading worldwide at an alarming rate. 
Currently, the pandemic is of paramount 
importance and poses a serious threat to public 
health and requires global collaboration to be 
controlled (1). In most cases, COVID-19 presents 
with unspecific symptoms such as dry cough, fever, 
and fatigue, but it is a life-threatening disease that 
can cause serious medical conditions (2-5). The 
clinical course of COVID-19 infection differs from 
one patient to another  and varies from no 
symptoms to respiratory failure, septic shock, and 
coagulation dysfunction (6-10). 
Several studies have recommended chest 
computed tomography (CT) scan as a diagnostic 
and also prognostic tool in COVID-19 patients (11-
15). A cohort study among 1014 patients in Wuhan, 
China, reported that chest CT scan had 97% 
sensitivity, 25% specificity, and 68% accuracy in 
the diagnosis of COVID-19 (16). Based on the 
existing studies, peripheral ground-glass opacity is 
the most frequent and typical finding of COVID-19 
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infection in chest CT scans (17, 18). Other findings, 
such as consolidations, vascular changes, bronchial 
wall thickness, pleural effusion, the crazy-paving 
sign, halo and reversed-halo sign, reticular pattern, 
and fibrotic pattern are mostly observed in the 
recovery phase of the disease (19-21). 
Like other diseases, the prognosis of COVID-19 
patients is of undisputed importance and requires 
clinical and paraclinical details. Several studies 
have shown that there is a correlation between 
chest CT scan findings and prognosis of the 
patients. For example, One study revealed that CT 
scan findings in patients with severe lung 
involvements have mostly had central patterns 
(22). Some studies found that a poor prognosis of 
COVID-19 was mostly related to higher chest 
involvements on the CT scan (23, 24). The 
development of pulmonary consolidation may be a 
red flag of severe disease (25). Likewise, several 
studies have reported that patients with severe 
COVID-19 infection have shown a higher rate of 
bronchial wall thickness, the crazy-paving sign, 
mediastinal lymphadenopathy, and pleural 
effusion in their chest CT scans (13, 26, 27). 
There is no rapid scoring tool based on qualitative 
and quantitative findings that can help predict the 
patient outcomes upon their emergency 
department (ED) admission. The aim of this study 
was to provide a prognostic assessment tool based 
on chest CT scan findings to predict 30-day adverse 
outcomes in new-onset COVID-19 patients who 
were hemodynamically stable and did not require 
immediate critical care at the time of ED admission. 
Methods 
Study design 
This derivation study was conducted at the ED of a 
university-affiliated hospital in Tehran, Iran. The 
implementation of the project was approved by the 
ethics committee of Tehran University of Medical 
Sciences. All the data obtained were analyzed and 
reported anonymously. 
Study population 
All people over 18 years of age with new-onset 
COVID-19 symptoms (over the past 72 hours) 
presenting to the ED from 20 February to 20 March, 
2020, were included. Convenience sampling was 
used in this research. As this was a pilot study, we 
applied the rule of thumb to estimate the sample 
size. 
The primary diagnosis of COVID-19 was made 
based on a physical examination and paraclinical 
tests. The patients underwent a chest CT scan 
immediately after their ED admission. Siemens® 
Somatom Emotion multi-slice CT scanner was used 
for this purpose, as it allows high-resolution thin 
slice scanning with collimation as thin as 16*0.6 
mm or 6*0.5 mm. 
In addition, the reverse transcription-polymerase 
chain reaction (RT-PCR) test was performed in all 
the patients as the gold standard test. Two 
nasopharyngeal specimens were obtained 
immediately after the admission and the following 
day in this regard. 
The exclusion criteria were as follows: Having 
unstable clinical conditions (loss of consciousness, 
unstable hemodynamic status, shock index more 
than one, and respiratory failure requiring 
immediate invasive mechanical ventilation), 
needing immediate critical care at the time of ED 
admission, pregnancy (as these candidates were 
referred to the nearest women’s hospital), those 
leaving the ED against medical advice or having had 
two consecutive negative RT-PCR test results. 
Data collection 
Demographic data, including age, gender, and 
comorbidities, including hypertension (HTN), 
diabetes mellitus (DM), chronic renal failure (CRF), 
coronary artery disease (CAD), and cirrhosis, were 
extracted from the medical documents of the 
patients. A radiologist reported the findings, 
including the number of affected lobes, appearance 
of ground-glass nodules, patch B/punctate ground-
glass opacities, patch C consolidations, fibrous 
stripes, irregular solid nodules, cavitation, pleural 
effusion, pleural thickness, signs of pleural 
reaction, lymphadenopathy, calcification, 
bronchiectasis, the reversed-halo sign, the crazy-
paving sign, bronchial wall thickness, pulmonary 
emphysema, air bronchogram signs and vascular 
enlargement, lobe severity score, lateralization of 
findings, i.e., bilateral or unilateral, distribution of 
findings, i.e., subpleural, perihilar, central, focal, 
multifocal, and diffused.  
The severity of lung involvement was evaluated in 
the five lung lobes and scores of 0, 1, 2, 3, and 4 
were taken as none (0%), minimal (1 to 25%), mild 
(26 to 50%), moderate (51 to 75%), and severe (76 
to 100%) lung involvement, respectively (28). The 
total lobe severity score (TSS) was calculated by 
summing up the scores from the five lobes (left 
upper lobe, left lower lobe, right upper lobe, right 
middle lobe, and right lower lobe). 
Finally, the patient outcomes (after 30 days), 
including death, ICU admission with or without 
intubation, or discharge from the hospital, were 
extracted from their medical documents. The 
outcome was also divided into two different 
groups, including adverse outcomes (death or ICU 
admission with or without intubation) and 
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discharge from the hospital. 
Eventually, TSS was used as a prediction tool based 
on the chest CT scan findings for the adverse 
outcomes of COVID-19. We categorized age into 
above and under 60 years old and added one score 
to TSS for patients over age 60 years, and named it 
model 2. In addition, in model 3, we added one 
score to model 2 for patients with at least one 
comorbidity such as HTN, DM, CRF, and CAD. 
Finally, the accuracy of these three models in 
predicting adverse outcomes was examined. 
Statistical analysis 
All the statistical analyses were performed using 
STATA 14 (StataCorp, Texas, USA). The 
Kolmogorov-Smirnov test was used to assess the 
normal distribution of the variables. Continuous 
variables were described using the mean ± SD, and 
categorical variables using frequency and 
percentage of the data. Due to the normality of the 
variables’ distribution, parametric tests were 
applied to investigate the relationship between the 
variables. The relationship between the continuous 
and categorical variables was examined using the 
Independent-Sample t-test and the one-way 
ANOVA.  
The relationship between the categorical variables 
was examined using the Chi-square test or Fisher’s 
Exact test. The sensitivity, specificity, positive 
likelihood ratio (PLR), and negative likelihood ratio 
(NLR) of different cut-off points of the TSS, model 2 
(TSS with age) and model 3 (model 2 with 
comorbidity) scores were calculated and presented 
with a 95% confidence interval (CI). The ROC curve 
and the area under the curve (AUC) were also 
examined, and the AUC difference of model 2 and 3 
with TSS compared with the Chi-square test and 
Bonferroni’s method. The optimal cut-off point was 
determined based-on Youden's J statistic. P < 0.05 
was considered statistically significant. 
RESULTS 
In our study, 187 patients were recruited, of whom 
50 patients left the ED against medical advice, and 
137 patients with a mean age of 59.9±16.8 years 
(62.0% male) were included in the final analysis. 
The frequency of death, ICU admission with or 
without intubation, and discharged patients was 49 
(35.8%), 22 (16.1%), and 66 (48.2%), respectively.  
The mean age in patients with adverse outcomes 
was 66.6±14.6, which is significantly higher than 
the mean age of the discharged patients 
(59.2±16.2) (p<0.001). Also, the history of HTN, 
DM, CRF, or CAD was significantly higher in 
patients with adverse outcomes than the 
discharged patients. The history of HTN, DM, CRF, 
and CAD was significantly higher in those with 
adverse outcomes (78.9%) than the discharged 
patients (24.2%) (p<0.001) (Table 1).  
Of the 137 patients who underwent chest 
computed tomography, the prevalence of patients 
with 0, 1, and ≥ 2 affected lobes was 4.5%, 13.6%, 
and 81.9%, respectively. The adverse outcome was 
significantly higher in patients with more than two 
lung-affected lobes (93.0% vs. 81.8%, p=0.048). 
The prevalence of bilateral lung involvement was 
94.8%. The most common chest CT scan findings 
were patch B/punctate ground-glass opacity 
(92.0%), ground glass nodule (67.2%), air 
bronchogram signs (61.3%) and fibrous stripes 
(58.4%). 
Of the CT scan findings, patch B/ punctate ground-
glass opacity (97.2% vs. 86.4%, p=0.020), 
bronchiectasis (29.6% vs. 10.6%, p=0.006), the 
crazy-paving sign (29.6% vs. 4.5%, p<0.001) was 
significantly higher in patients with adverse 
outcomes than the discharged patients. 
Nevertheless, lymphadenopathy was significantly 
higher in the discharged patients (4.2% vs. 19.7%, 
p=0.005).  








P-Value a P-Value b Death 
(n=49) 
ICU and/or Intubation 
(n=22) 
Age, mean±SD 59.9±16.8 70.1±12.8 58.7±15.5 52.9±16.2 <0.001 <0.001 
Sex; male, n (%) 85 (62.0) 29 (59.2) 14 (63.6) 42 (63.6) 0.876 0.711 
Comorbidities, n (%)       
Hypertension 46 (33.6) 26 (53.1) 7 (31.8) 13 (19.7) 0.001 0.001 
Diabetes Mellitus 29 (21.2) 21 (42.9) 6 (27.3) 2 (3.0) <0.001 <0.001 
Chronic Renal Failure 11 (8.0) 8 (16.3) 3 (13.6) 0 (0.0) 0.001 0.001 
Coronary Artery Disease 50 (36.5) 29 (59.2) 11 (50.0) 10 (15.2) <0.001 <0.001 
Cirrhosis 3 (2.2) 2 (4.1) 0 (0.0) 1 (1.5) 0.749 1.0 
ICU: Intensive Care Unit; SD: Standard Deviation. 
aP-value refers to the relationship of each variable between three patients' outcomes;  
bP-value refers to the relationship of each variable between two patients' outcome (adverse outcomes and discharge) 
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The perihilar (p=0.014), central (p<0.001), and 
diffused (p<0.001) distribution of CT scan findings 
was significantly higher in patients with adverse 
outcomes, but multifocal distribution was 
significantly higher in the discharged patients 
(p<0.001) (Table 2). The prevalence of cavitation 
and vascular enlargement was zero.  
The mean severity lobe score in all five lobes was 
significantly higher in the patients with adverse 
outcomes. The mean TSS in patients with adverse 
outcomes (9.4 ±3.2) was significantly higher than 
in the discharged patients (7.2±3.3) (p<0.001).  
The ROC analysis showed that the AUC of TSS for 
the prognosis of adverse outcomes was 0.703 (95% 
CI: 0.607 to 0.799). The optimal cut-off point of TSS 
had sensitivity and specificity in this cut-off point 
and was 64.4% and 74.1%, respectively. 
In the second predicting model (TSS with age), the 
AUC was 0.721 (95% CI: 0.628 to 0.814) and the 
sensitivity and specificity in the optimal cut-off 
point were 71.2% and 67.2%, respectively. 
In the third predicting model (TSS with age and 
comorbidity), the AUC was 0.755 (95% CI: 0.666 to 
0.844), and the optimal cut-off point had 79.7% 
sensitivity and 65.5% specificity. The optimal cut-
off point was more than 8 in all the three models 
(Table 3). The discrimination of model 3 based on 
Bonferroni’s test was significantly better than TSS 
(p<0.001), but model 2 was not significantly 
different with TSS (p=0.071) (Figure 1).  












Severity lobe score, mean±SD       
     LUL 1.2±0.73 1.4±0.79 1.4±0.82 0.93±0.57 0.002 <0.001 
     LLL 1.9±1.1 2.2±0.94 2.1±1.2 1.7±1.0 0.014 0.004 
     RUL 1.1±0.71 1.4±0.66 1.2±0.83 0.97±0.64 0.008 0.004 
     RML 1.9±0.86 2.2±0.79 1.8±0.83 1.7±0.87 0.005 0.013 
     RLL 2.0±1.1 2.4±0.99 1.8±0.98 1.8±1.1 0.008 0.030 
     TSS 8.3±3.4 9.8±2.9 8.4±3.5 7.2±3.3 0.001 <0.001 
More than two lobes affected, 
n (%) 
120 (87.6) 46 (93.9) 20 (90.9) 54 (81.8) 0.133 0.048 
CT scan findings*, n (%)       
     Ground glass nodule 92 (67.2) 35 (71.4) 16 (72.7) 41 (62.1) 0.479 0.227 
     Patch B/punctate ground-
glass opacity 
126 (92.0) 47 (95.9) 22 (100) 57 (86.4) 0.073 0.020 
     Patch C consolidation 63 (46.0) 27 (55.1) 7 (31.8) 29 (43.9) 0.171 0.643 
     Fibrous stripes 80 (58.4) 34 (69.4) 10 (45.5) 36 (54.5) 0.113 0.378 
     Irregular solid nodule 55 (40.1) 24 (49.0) 7 (31.8) 24 (36.4) 0.270 0.384 
     Pleural effusion 7 (5.1) 5 (10.2) 0 (0.0) 2 (3.0) 0.191 0.443 
     Pleural thickness 56 (40.9) 29 (59.2) 3 (13.6) 24 (36.4) 0.001 0.300 
     Pleural reaction signs 29 (21.2) 13 (26.5) 0 (0.0) 16 (24.2) 0.028 0.396 
     Lymphadenopathy  16 (11.7) 3 (6.1) 0 (0.0) 13 (19.7) 0.014 0.005 
     Calcification 4 (2.9) 1 (2.0) 0 (0.0) 3 (4.5) 0.656 0.352 
     Bronchiectasis 28 (20.4) 18 (36.7) 3 (13.6) 7 (10.6) 0.002 0.006 
     Reversed halo sign 13 (9.5) 2 (4.1) 2 (9.1) 9 (13.6) 0.220 0.110 
     The crazy-paving sign 24 (17.5) 15 (30.6) 6 (27.3) 3 (4.5) 0.001 <0.001 
     Bronchial wall thickness 51 (37.2) 23 (46.9) 4 (18.2) 24 (36.4) 0.067 0.840 
     Pulmonary emphysema 3 (2.2) 1 (2.0) 0 (0.0) 2 (3.0) 1.0 0.609 
     Air bronchogram signs 84 (61.3) 33 (67.3) 12 (54.5) 39 (59.1) 0.518 0.606 
Distribution, n (%)       
     Subpleural 120 (87.6) 46 (93.9) 16 (72.7) 58 (87.9) 0.044 0.922 
     Perihilar 128 (93.4) 48 (98.0) 22 (100) 58 (87.9) 0.062 0.014 
     Central  53 (38.7) 32 (65.3) 11 (50.0) 10 (15.2) <0.001 <0.001 
     Focal 7 (5.1) 3 (6.1) 1 (4.5) 3 (4.5) 0.879 1.0 
     Multifocal 51 (37.2) 12 (24.5) 2 (9.1) 37 (56.1) <0.001 <0.001 
     Diffused 31 (22.6) 20 (40.8) 8 (36.4) 3 (4.5) <0.001 <0.001 
Bilateral lungs, n (%) 127 (94.8) 48 (98.0) 21 (95.5) 58 (92.1) 0.334 0.253 
SD: Standard Deviation; ICU: Intensive Care Unit; LUL: Left Upper Lobe; LLL: Left Lower Lobe; RUL: Right Upper Lobe; RML: Right 
Middle Lobe; RLL: Right Lower Lobe; TSS: Total Lobe Severity Score; CT: Computed Tomography. 
aP-value refers to the relationship of each variable between three patients' outcomes;  
bP-value refers to the relationship of each variable between two patients' outcomes (Adverse outcomes and discharge) 
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DISCUSSION 
In the present study, the chest CT scan findings and 
demographic data of non-critical new-onset 
COVID-19 patients were evaluated to develop a 
useful tool for predicting the patients’ adverse 
outcomes. TSS, model 2 and model 3 were 
developed based on the chest CT scan findings, age 
range, and presence of at least one comorbidity. 
The results showed that TSS was significantly 
higher in those with adverse outcomes, and model 
3 at the cut-off point of more than 8 provided an 
acceptable sensitivity, specificity, and AUC for 
predicting adverse outcomes. The discrimination 
of model 3 was significantly better compared to 
TSS, but model 2 did not differ significantly with 
TSS. 
Previous studies have shown that some chest CT 
scan findings are more common in patients with 
severe COVID-19 infection. Khunhua et al. 
compared 25 critical cases of COVID-19 with 58 
controls and found that the frequency of 
consolidation, linear opacity, the crazy-paving sign, 
and bronchial wall thickness and TSS were higher 
in the critical cases (29). This result was consistent 
Table 3: The accuracy indices of TSS, model 2 (TSS with age) and model 3 (model 2 with comorbidity) for adverse outcomes of COVID-
19 
Cut-Off Point Model 
Sensitivity Specificity PLR NLR 
(95% CI) 
>7 
TSS 76.27 (63.4 - 86.4) 55.17 (41.5 - 68.3) 1.70 (1.2 - 2.3) 0.43 (0.3 - 0.7) 
Model-2 81.36 (69.1 - 90.3) 50.00 (36.6 - 63.4) 1.63 (1.2 - 2.2) 0.37 (0.2 - 0.7) 
Model-3 86.44 (75.0 - 94.0) 46.55 (33.3 - 60.1) 1.62 (1.2 - 2.1) 0.29 (0.1 - 0.6) 
>8* 
TSS 64.41 (50.9 - 76.4) 74.14 (61.0 - 84.7) 2.49 (1.5 - 4.0) 0.48 (0.3 - 0.7) 
Model-2 71.19 (57.9 - 82.2) 67.24 (53.7 - 79.0) 2.17 (1.5 - 3.3) 0.43 (0.3 - 0.7) 
Model-3 79.66 (67.2 - 89.0) 65.52 (51.9 - 77.5) 2.31 (1.6 - 3.4) 0.31 (0.2 - 0.5) 
>9 
TSS 47.46 (34.3 - 60.9) 82.76 (70.6 - 91.4) 2.75 (1.5 - 5.1) 0.63 (0.5 - 0.8) 
Model-2 57.63 (44.1 - 70.4) 75.86 (62.8 - 86.1) 2.39 (1.4 - 4.0) 0.56 (0.4 - 0.8) 
Model-3 67.80 (54.4 - 79.4) 72.41 (59.1 - 83.3) 2.46 (1.6 - 3.9) 0.44 0.3 - 0.7) 
CI: Confidence Interval; PLR: Positive Likelihood Ratio; NLR: Negative Likelihood Ratio; TSS: Total Lobe Severity Score. Model 2: TSS 
with age; Model 3: Model 2 with comorbidity. 
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with the present findings, but our different 
frequent CT scan findings may be attributed to the 
assessment of critical cases in Khunhua’s research 
and non-critical cases in our study.  
Our study showed that CT-scan findings were 
mostly distributed peripherally and bilaterally. 
Similarly, Zhao et al. conducted a study on the chest 
CT scan findings of 101 COVID-19 patients and 
showed that 87.1% and 82.2% of the patients had 
peripheral distributions and bilateral 
involvements (27). The most common lesions in 
the CT scan findings in our study were ground-
glass opacity, followed by ground glass nodules. 
These results are consistent with the findings of 
some other studies (17-19). Contrary to our 
findings, one study revealed that the frequency of 
pleural effusion was higher in the patients with 
severe COVID-19 infection, which may reflect their 
higher viral load (27). Our study found no 
significant relationship between pleural effusion 
and the patients’ outcomes.  
Many reports have assessed chest CT scan findings 
in COVID-19 patients (18, 30) as well as their 
clinical features (31, 32), but providing a rapid 
scoring tool for use in the ED is a notable 
achievement of this study. In this research, model 
3, which consists of TSS, age, and history of at least 
one comorbidity, was used to predict the 
probability of 30-day adverse outcomes. This 
prediction model can be applied to quickly detect 
the probability of death and ICU admission in 
COVID-19 patients who are initially stable at the 
time of ED admission. Therefore, this model can 
prompt medical teams to pursue more proficient 
monitoring and patient care to avoid adverse 
outcomes. 
Limitations 
An important drawback of the present study was 
its small sample size. Although the developed 
scoring tool is easy to use in EDs, it is not applicable 
where there is limited access to modern CT 
scanners. The density of the lesions was not 
evaluated in the present study, while some other 
studies have proposed different densities of lesions 
based on the severity of the infection (33).  
Finally, the information about the patients’ lung 
status before COVID-19 onset was not accessible, 
which has probably affected our findings. It is 
highly recommended to perform further studies 
with a large sample size to validate a more accurate 
scoring tool.  
CONCLUSIONS 
The present study developed a scoring tool for non-
critical new-onset COVID-19 patients in EDs based 
on their CT scan findings and basic demographic 
data. TSS, in combination with age range and 
history of at least one comorbidity, at the cut-off 
point of more than 8, provided a useful measure for 
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